Every 10-Q that AN2 Therapeutics, Inc. (ANTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ANTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANTX filings page.
AN2 Therapeutics, Inc. reported its June 30, 2026 quarter as a clinical‑stage company with no product revenue and continued R&D investment across hematologic, infectious disease and oncology programs. The pipeline includes three Phase 2 studies expected to be active in 2026 and multiple preclinical candidates.
For the quarter, net loss was $8.2 million versus $6.5 million a year earlier, driven mainly by higher research and development expenses of $6.0 million. General and administrative expenses declined to $2.9 million. Six‑month net loss was $18.2 million compared with $17.1 million in the prior‑year period.
Liquidity improved through financings. As of June 30, 2026, cash, cash equivalents and investments totaled $79.9 million, up from $61.9 million at year‑end, reflecting a March 2026 private placement of common stock and pre‑funded warrants and sales under a new at‑the‑market equity program. Management states these resources are expected to fund the current operating plan for at least twelve months from the financial statement issuance date.
AN2 Therapeutics reported a Q1 2026 net loss of $10.0M, slightly improved from $10.6M a year earlier, as operating expenses declined modestly. Research and development was $6.7M, reflecting its focus on advancing a boron-chemistry small-molecule pipeline across hematologic, infectious disease, and oncology indications.
Cash, cash equivalents and investments totaled $85.3M as of March 31, 2026, boosted by a March 2026 private placement that raised roughly $40.0M in gross proceeds through common stock and pre-funded warrants. Management believes this cash will fund the current operating plan for at least twelve months.
Clinically, AN2 plans a Phase 2 proof-of-concept study of epetraborole in polycythemia vera starting in Q3 2026, supports an investigator-initiated trial in M. abscessus lung disease with topline data expected in late 2027, and has completed Phase 1 dosing of AN2-502998 for chronic Chagas disease ahead of Phase 1/NHP data in Q2 2026 and a planned Phase 2 later in 2026. The company also declared an ENPP1 oncology candidate and continues discussions with U.S. agencies to fund Phase 2 development of epetraborole for acute melioidosis.
AN2 Therapeutics (ANTX) filed its Q3 2025 10‑Q reporting lower losses and steady liquidity. For the quarter, operating expenses were $10.0 million, driven by $7.0 million in research and development and $3.0 million in general and administrative costs. Interest income of $0.7 million partially offset expenses, resulting in a net loss of $9.4 million, or $0.31 per share.
Cash, cash equivalents, and investments totaled $65.1 million, with management stating this is sufficient to fund its operating plan for at least 12 months from the financial statement issuance date. Year‑to‑date, operating cash outflows were $24.6 million, and the nine‑month net loss improved to $26.5 million from $43.8 million a year ago as expenses declined.
The company recorded reductions to research and development expense from non‑dilutive funding, including $3.5 million year‑to‑date from a NIAID contract and $1.5 million from a Gates Foundation grant. In June, 2,952,000 common shares were exchanged for pre‑funded warrants at a nominal exercise price. Shares outstanding were 27,402,024 as of November 3, 2025.
AN2 Therapeutics (ANTX) reported interim results showing continued clinical progress and a tighter cash position. Total cash, cash equivalents and investments were $71.2 million as of June 30, 2025, with cash and cash equivalents of $18.22 million and short- and long-term investments of $44.70 million and $8.30 million, respectively. Management believes these resources are sufficient to fund the company’s current operating plan for at least 12 months.
The company recorded a $17.1 million net loss for the six months ended June 30, 2025 (versus $31.1 million in the comparable 2024 period), driven by research and development and general and administrative expenses. AN2 advanced AN2-502998 into Phase 1 start-up activities and completed dosing of the first single ascending dose cohort (reported events in May and August 2025). Funding arrangements include government and foundation awards, but a NIAID contract was reduced by $9.0 million to a cumulative $9.3 million commitment. The company continues to rely on external financing and grants while it advances multiple boron-chemistry programs.